Bronte Capital Management Pty Ltd.
Position in NKTR — Nektar Therapeutics
CIK 1471085
Bondi Junction, C3
Position in NKTR
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$13,852,677
-$411,842 QoQ
Shares Held
198,434
+0.1% QoQ
Ownership
0.581%
of shares outstanding
% of Portfolio
1.78%
of 13F equity value
Holder Rank
#40
of 239 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NKTR Over Time
Shares Held
Position Value (USD)
Derivatives in NKTR
reported options exposure · as of Mar 31, 2026CallValue
$14,569,875
CallShares
202,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bronte Capital Management Pty Ltd. holds $129,800,452 across 16 Biotechnology names. NKTR ranks #2 (10.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
162,618 | $101,398,827 | |
| 2 | NKTR |
Nektar Therapeutics
This page
|
198,434 | $13,852,677 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
35,384 | $10,651,645 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
18,780 | $3,517,118 | |
| 5 | FATE |
Fate Therapeutics Inc
|
21,740 | $58,698 | |
| 6 | ANTX |
AN2 Therapeutics, Inc.
|
10,895 | $52,731 | |
| 7 | CCCC |
C4 Therapeutics, Inc.
|
10,349 | $48,329 | |
| 8 | ALXO |
Alx Oncology Holdings Inc
|
18,095 | $37,456 |
All Filings in NKTR
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,852,677 | 198,434 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $14,264,519 | 198,256 | Shares | Sole | 2026-04-27 | |
| 2026-03-31 | $14,569,875 | 202,500 | Call | Sole | 2026-04-27 | |
| No filing history on record for this holder in this stock. | ||||||